ImmuCell (NASDAQ:ICCC) Stock Passes Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• ImmuCell (ICCC) crossed above its 200-day moving average, with the 200-day MA at $6.30 and the stock trading as high as $8.50 and last at $8.44 on light volume (~16,323 shares).
• Analyst sentiment is negative: Weiss Ratings downgraded the stock from "hold (c-)" to "sell (d-)" and the stock's average analyst rating on MarketBeat is "Sell".
• Fundamentals and ownership: the company has a small market cap (~$76.36M), a negative P/E (-76.72), conservative leverage and strong liquidity (current ratio 4.26), and institutional investors own about 13.47% after several recent stake increases.

Shares of ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.30 and traded as high as $8.50. ImmuCell shares last traded at $8.44, with a volume of 16,323 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of ImmuCell from a "hold (c-)" rating to a "sell (d-)" rating in a research note on Monday, April 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of "Sell".

ImmuCell Price Performance

The stock has a market cap of $76.36 million, a price-to-earnings ratio of -76.72 and a beta of 0.30. The stock has a fifty day simple moving average of $6.85 and a 200-day simple moving average of $6.30. The company has a current ratio of 4.26, a quick ratio of 1.93 and a debt-to-equity ratio of 0.28.

Institutional Investors Weigh In On ImmuCell

A number of institutional investors have recently bought and sold shares of ICCC. Geode Capital Management LLC boosted its position in shares of ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock valued at $500,000 after acquiring an additional 2,907 shares in the last quarter. Mesirow Financial Investment Management Inc. lifted its stake in ImmuCell by 199.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company's stock worth $224,000 after purchasing an additional 24,303 shares during the period. Finally, Steadtrust LLC lifted its stake in ImmuCell by 79.1% during the fourth quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company's stock worth $349,000 after purchasing an additional 25,070 shares during the period. Institutional investors and hedge funds own 13.47% of the company's stock.

ImmuCell Company Profile

ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.